Can Twist Bioscience (TWST) Stock Reach $190?

Twist Bioscience Corporation (TWST), the South San Francisco-based synthetic DNA manufacturer, has been one of 2026's most volatile life-science tools names, surging from a 52-week low near $23 to an October peak above $219 before pulling back sharply. The central question for investors now is whether the shares can climb back toward a $190 price target. The answer is far from settled, resting on a tug-of-war between explosive AI-driven demand and a valuation that leaves little room for execution missteps.

Key Takeaways

• The central target examined here is $190, roughly 27% above the latest verified close of $149.13 (October 21, 2026).
• Because the stock has already surged past most published targets, this $190 figure is the average of the six current analyst price targets that sit above the share price, not the full consensus.
• The six above-price targets are Barclays ($215), Guggenheim ($212), Canaccord Genuity ($205), TD Cowen ($190), Leerink Partners ($190), and Jefferies ($150), with a raw mean near $194.
• The overall average of all roughly 11 current, valid targets is only about $153, and the full range is extraordinarily wide, from $45 (BWS Financial, Sell) to $215 (Barclays, Buy).
• Bull case: triple-digit growth in AI-enabled drug discovery orders and a stated path to positive adjusted EBITDA. Bear case: persistent losses, a valuation near 27 times trailing sales, insider selling, and dilution risk.

Analyst Price Targets and Consensus View

Twist Bioscience's analyst coverage reflects a genuine split of opinion. Rating a stock that has roughly tripled year to date, most sell-side firms remain constructive, but a handful are decidedly cautious. Recent moves show the momentum: Barclays raised its target to $215 (October 7), Guggenheim to $212 (October 1), Canaccord Genuity to $205 (October 12), TD Cowen to $190 (October 13), and Leerink Partners to $190 (September 29). Jefferies initiated coverage with a Hold and a $150 target (October 8), while UBS initiated with a Neutral at $144 (September 9).

The caution is real. Evercore ISI downgraded the stock to In Line in early July, and BWS Financial carries a $45 Sell rating. Because several targets set before the autumn re-rating still sit below the current price, the unweighted average of all valid targets is only about $153, essentially in line with the market. Applying a minimum-distance approach, the central target used here is the average of the six targets above the current price, roughly $194, rounded to $190 for readability. That dispersion, from $45 to $215, is a warning in itself: no single "analyst consensus" number captures this stock's range of outcomes.

Current Market Position and Path Toward the Target

With TWST at $149.13, reaching $190 requires a rise of about 27%, a substantial but not unprecedented move for a stock that gained more than 300% over the trailing year. The shares remain about 32% below their October 6 intraday high of $219.71, and the recent action has been choppy, with the stock swinging between roughly $131 and $160 over the past several sessions.

The path toward $190 depends less on a single catalyst than on whether the market continues to reward the company's AI narrative. Twist's silicon-based platform for manufacturing synthetic DNA is increasingly viewed as a pick-and-shovel exposure to AI-enabled drug discovery. Management has guided to triple-digit growth in AI-related drug discovery orders into 2026 and 2027 and expects to reach positive adjusted EBITDA by the fourth quarter of fiscal 2026 and for all of fiscal 2027. If those milestones land on schedule, the valuation could hold or expand; if they slip, a stock trading near 27 times trailing sales and still posting negative earnings per share (EPS) could compress quickly.

What Could Support a Move Toward the Target

• AI-driven demand: Rising orders tied to AI-enabled drug discovery are the core bullish thesis, with analysts citing this as the key reason for their target increases.
• Raised guidance: The company lifted its fiscal 2026 revenue outlook, with consensus projecting roughly $456 million in revenue, up about 21% year over year.
• Margin progress: Gross margin reached about 52% in the June quarter, and management's EBITDA-inflection guidance signals improving operating leverage.
• Platform differentiation: Twist's proprietary silicon-chip DNA synthesis approach offers a cost and scale advantage that supports durable market share in synthetic genes and NGS (next-generation sequencing) tools.

What Could Prevent the Target From Being Reached

• Valuation risk: At roughly 27 times trailing sales and with negative EPS and EBITDA, the stock prices in substantial future growth that has not yet converted to profit.
• Small AI contribution today: Independent commentary has noted AI-related revenue may still be a modest share of near-term sales, meaning the narrative could outrun the fundamentals.
• Insider selling and dilution: Insider sentiment has been negative, and a $200 million equity program established in June 2026 raises the prospect of share issuance.
• Regulatory and safety concerns: Some analysts have flagged bioweapon and AI-safety questions, though they generally view existing safeguards as adequate.
• Extreme volatility: With a beta above 2, the stock is prone to sharp drawdowns, as the roughly 32% retreat from the October high demonstrates.

Technical Levels and Market Structure

The technical picture is defined by the dramatic run and retreat. The 52-week range spans $23.30 to $219.71. After peaking in early October, the shares pulled back and have found recent support in the $130-to-$135 zone, with the psychologically significant $150 level acting as near-term resistance. Above that, the $200-to-$220 band marks the prior high area and a likely zone of selling pressure. A durable reclaim of $160 would be an early sign of renewed momentum, while a breakdown below $130 would suggest the correction has further to run.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms' time frames can differ. The next major catalyst is the fiscal fourth-quarter earnings report expected in mid-November 2026. Investors should watch revenue and guidance against consensus, the trajectory of AI-enabled drug discovery orders, progress on the EBITDA-inflection timeline, any equity issuance under the $200 million program, and insider transaction trends. Broader life-science tools sentiment and interest-rate expectations will also influence how much the market is willing to pay for an unprofitable, high-growth name.

AI Daily Buy/Sell Signals

For traders seeking a systematic way to track names like TWST, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to traditional research. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. This can help active investors uncover opportunities, monitor existing positions, and identify changing trends more efficiently than manual screening. Exploring these AI Daily Buy/Sell Signals can be a practical way to add a systematic layer to your decision-making.

Final Assessment

The $190 central target for Twist Bioscience represents a roughly 27% move from the current $149.13 price, and it is the average of the six analyst targets that still sit above the market, not a full-street consensus. The strongest supports are genuine: accelerating AI-enabled drug discovery orders, raised revenue guidance, and a credible path toward positive adjusted EBITDA. The principal obstacles are equally real: persistent losses, a rich multiple near 27 times sales, insider selling, dilution risk, and a wide $45-to-$215 analyst range that signals deep disagreement. Whether TWST can reach $190 hinges on execution and whether investors continue to pay a premium for the AI story through the upcoming earnings report and beyond. No outcome is guaranteed, and the wide dispersion of analyst views should give investors pause before anchoring to any single number.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations